Challenges and Impact of Formulation on Exposure to Drive PKPD in CNS Drug Discovery

• Early discovery compound characteristics often make high exposure for PKPD necessary and difficult to achieve
• Driving CNS exposure is even more challenging due to the blood brain barrier
• Dosing strategies to address this challenge are complicated and yield mixed results

Doug Burdette, Director, DMPK, Biogen